Abstract:Rationale: Bitter taste receptors (TAS2Rs) are abundantly expressed in airway smooth muscle cells (ASMCs), which have been recognized as promising targets for bitter agonists to initiate relaxation and thereby prevent excessive airway constriction as the main characteristic of asthma. However, due to the current lack of tested safe and potent agonists functioning at low effective concentrations, there has been no clinically approved TAS2R-based drug for bronchodilation in asthma therapy. This study thus aimed at exploring TAS2R agonists with bronchodilator potential by BitterDB database analysis and cell stiffness screening. Methods: Bitter compounds in the BitterDB database were retrieved and analyzed for their working subtype of TAS2R and effective concentration. Compounds activating TAS2R5, 10, and 14 at < 100 μM effective concentration were identified and subsequently screened by cell stiffness assay using optical magnetic twisting cytometry (OMTC) to identify the most potent to relax ASMCs. Then the compound identified was further characterized for efficacy on various aspects related to relaxation of ASMCs, incl. but not limited to traction force by Fourier transform traction force microscopy (FTTFM), [Ca2+]i signaling by Fluo-4/AM intensity, cell migration by scratch wound healing, mRNA expression by qPCR, and protein expressing by ELISA. The compound identified was also compared to conventional β-agonist (isoproterenol and salbutamol) for efficacy in reducing cell stiffness of cultured ASMCs and airway resistance of ovalbumin-treated mice. Results: BitterDB analysis found 18 compounds activating TAS2R5, 10, and 14 at < 100 μM effective concentration. Cell stiffness screening of these compounds eventually identified flufenamic acid (FFA) as the most potent compound to rapidly reduce cell stiffness at 1 μM. The efficacy of FFA to relax ASMCs in vitro and abrogate airway resistance in vivo was equivalent to that of conventional β-agonists. The FFA-induced effect on ASMCs was mediated by TAS2R14 activation, endoplasmic reticulum Ca2+ release, and large-conductance Ca2+-activated K+ (BKCa) channel opening. FFA also attenuated lipopolysaccharide-induced inflammatory response in cultured ASMCs. Conclusions: FFA as a potent TAS2R14 agonist to relax ASMCs while suppressing cytokine release might be a favorite drug agent for further development of TAS2R-based novel dual functional medication for bronchodilation and anti-inflammation in asthma therapy.

Discovery of a Highly Selective β 2 -Adrenoceptor Agonist with a 2-Amino-2-phenylethanol Scaffold as an Oral Antiasthmatic Agent

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Discovery and Identification of Novel 5-Hydroxy-4 H -benzo[1,4]oxazin-3-one Derivatives as Potent β 2 -Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

[Design, Synthesis and Antiasthmatic Activities of NO-donating Seratrodast Derivatives].

Discovery of Dual-Target Ligands Binding to Beta2-Adrenoceptor and Cysteinyl-Leukotriene Receptor for the Potential Treatment of Asthma from Natural Products Derived DNA-encoded Library.

Dual Β2-Adrenoceptor Agonists-Pde4 Inhibitors for the Treatment of Asthma and COPD

New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid

Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

Beta-adrenoceptor agonists and asthma--100 years of development

Design, Synthesis and Evaluation of Dual Pharmacology Β2-Adrenoceptor Agonists and PDE4 Inhibitors

Discovery of Novel Antagonists on Β2-Adrenoceptor from Natural Products Using a Label-Free Cell Phenotypic Assay.

Synthesis, Purification, And Selective Beta(2)-Ar Agonist And Bronchodilatory Effects Of Catecholic Tetrahydroisoquinolines From Portulaca Oleracea

Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Stepwise Frontal Analysis Coupled with Affinity Chromatography: A Fast and Reliable Method for Potential Ligand Isolation and Evaluation from Mahuang-Fuzi-Xixin Decoction

Synthesis and blocking activities of a new class of α₁-adrenoceptor antagonists.

BitterDB database analysis plus cell stiffness screening identify flufenamic acid as the most potent TAS2R14-based relaxant of airway smooth muscle cells for therapeutic bronchodilation

Identifying the Antiasthmatic Target of Doxofylline Using Immobilized Β2 -Adrenoceptor Based High-Performance Affinity Chromatography and Site-Directed Molecular Docking.

Discovery of a novel BLT2 antagonist for the treatment of inflammatory airway diseases